This weekend was abuzz with the pharma industry bigwigs who had gathered at the 15th edition of the Bio Asia Summit. CNBC-TV18’s Ekta Batra was there as well and she caught up with Satish Reddy, Chairman of Dr Reddy's to talk about the pricing pressure and the way ahead.

FM's universal healthcare proposal a step in right direction: DRL

In an exclusive conversation with CNBC-TV18's Nitya Balakrishnan, Saumen Chakraborty of DRL adds that the company will maintain its capex target of Rs 1,000 crore for FY19, and it will focus on biological research and development (R&D).

TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study

Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO

Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.

New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.

Preparing for GST implementation for past few months: DRL's Chakraborty

In the latest, CNBC-TV18's Ekta Batra and Vikas Dandekar caught up with Saumen Chakraborty, CFO of Dr Reddy's Laboratories (DRL) and asked him amongst other things, if pharmaceutical companies like DRL will feel the jitters once GST is rolled out.

Govt needs to be a strong enabler in pharma sector: Experts

Shereen Bhan speaks with top bosses from the pharma sector along with KT Rama Rao, Minister of IT, Telangana at Bioasia 2017 to discuss way forward for pharma sector in making India healthier.

Expect US FDA approvals to pick going forward: Dr Reddy's

Saumen Chakraborty, CFO of Dr Reddy's is confident of getting back on to the growth path starting FY18 on the back of more than 15 significant launches and approvals that will help the pharma major make a comeback.

No scope of US intervention in Indian pharma cos: Wockhardt

Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

Lupin to see approvals after US FDA gives clean chit: Macquarie

Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.

Hope to commercialise 4 products acquired from Teva by FY18: DRL

Saumen Chakraborty, CFO of the company told CNBC-TV18 that they hope to commercialise four out of the eight products by FY18. He said all the eight products are expected to have limited competition.

After DRL-Teva, expect more M&A action in pharma: Prabhudas

Pharma companies are losing market share and such deals help them,says Surajit Pal of Prabhudas Lilladher.

US FDA issues shouldn't be overbearing factor for pharma: Citi

Executives of Dr Reddy's Laboratories and Citi tell CNBC-TV18 that the second half of 2016 should be a good one for pharma industry.

Regulatory issues discussed in Feb meet with US, Europe: DRL

Company will continue with tie-ups for biosimilar products. These will first be launched in India and then in other markets, says Satish Reddy, Chairman of Dr Reddy‘s Lab.

Indian pharma cos need to step-up safeguards at plants: Handa

In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

20% of Cipla FY17 revenues to come from US: Chirag Talati

When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

Board to consider buyback of equity shares on Feb 17: Dr Reddy's

Saumen Chakraborty, President and CFO, Dr Reddy's Lab said they will be making a proposal to the board for buying back equity shares on February 17.

Pharma cos capable of resolving FDA concern in 12-15 months:IIFL

Sharma, however, believes that despite the issues getting compounded by the day, most of the companies have enough capabilities to resolve them within the next 12-15 months.

Pharma cos facing pricing pressure in US: PhillipCap

In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.

USFDA warning: Have 15 days to respond, says DRL CFO

Saumen Chakraborty, CFO, Dr Reddy's Laboratories, says "The warning letter has come telling the management to respond within 15 working days in terms of strategy and plan."

Elepsia drug more relevant to Sun Pharma: Phillipcap

Surya Narayan Patra of Phillipcapital says the news on Elepsia is more relevant to Sun Pharma. The product was linked to one of the facilities linked to USFDA issues

Plan to revamp systems as per FDA expectations: Dr Reddy's

Speaking on acquisitions, Satish Reddy, Chairman of Dr Reddy's said they are always on the lookout for strategic fits to boost growth.

Eye significant growth in acquired UCB drugs: Dr Reddy's

According to Alok Sonig of DRL, the acquired brands have grown historically at lower double-digits and have a lot of headroom to grow further

See Rs 400cr increase in top line over next few yrs: Hetero

The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.

Core generics, API biz to drive FY16 growth: Dr Reddy's

GV Prasad, Co-Chairman & CEO of Dr Reddy‘s Laboratories said a lot of growth is seen in emerging markets